Attovia Therapeutics 在IPO规模扩大至2.89亿美元后，有望在纳斯达克上市首日大涨

路透中文

08/05

BUZZ-<a href="https://laohu8.com/S/ATTO">Attovia Therapeutics</a> 在IPO规模扩大至2.89亿美元后，有望在纳斯达克上市首日大涨

8月5日 - ** 阿托维亚治疗公司（Attovia Therapeutics，股票代码： ATTO.O）在将美国首次公开募股（IPO）规模扩大至2.89亿美元后，其纳斯达克首日上市开盘价有望远高于发行价

** 该股最新显示开盘价为每股24美元，而IPO发行价为17美元

** 总部位于加利福尼亚州圣卡洛斯的 ATTO（(link)）于周二晚间以每股17美元的价格售出1700万股 (link)，此次IPO规模已扩大 (link)

** ATTO公司致力于研发免疫介导性疾病的治疗方案，最初计划发行约1250万股，定价区间为每股15至17美元

** 其主要研发项目包括ATTO-1310，该药物正在开发用于治疗慢性瘙痒性疾病

** 摩根士丹利、Leerink Partners、花旗集团和加拿大皇家银行资本市场担任此次发行的联合簿记管理人

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2657452303"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2657452303\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2657452303?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-05 22:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657452303","market":"us","top_or_hot":-1,"title":"Attovia Therapeutics 在IPO规模扩大至2.89亿美元后，有望在纳斯达克上市首日大涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/ATTO\">Attovia Therapeutics</a> 在IPO规模扩大至2.89亿美元后，有望在纳斯达克上市首日大涨</title></head><body><p><span>8月5日</span><span> - </span>** 阿托维亚治疗公司（Attovia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>，股票代码： <span>ATTO.O</span>）在将美国首次公开募股（IPO）规模扩大至2.89亿美元后，其纳斯达克首日上市开盘价有望远高于发行价 </p><p>** 该股最新显示开盘价为每股24美元，而IPO发行价为17美元</p><p>** 总部位于加利福尼亚州圣卡洛斯的 ATTO（(<span>link</span>)）于周二晚间以每股17美元的价格售出1700万股 (link)，此次IPO规模已扩大 (<span>link</span>) </p><p>** ATTO公司致力于研发免疫介导性疾病的治疗方案，最初计划发行约1250万股，定价区间为每股15至17美元</p><p>** 其主要研发项目包括ATTO-1310，该药物正在开发用于治疗慢性瘙痒性疾病</p><p>** <a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>、Leerink Partners、<a href=\"https://laohu8.com/S/C\">花旗集团</a>和<a href=\"https://laohu8.com/S/RY\">加拿大皇家银行</a>资本市场担任此次发行的联合簿记管理人</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Attovia Therapeutics 在IPO规模扩大至2.89亿美元后，有望在纳斯达克上市首日大涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAttovia Therapeutics 在IPO规模扩大至2.89亿美元后，有望在纳斯达克上市首日大涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-08-05 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/ATTO\">Attovia Therapeutics</a> 在IPO规模扩大至2.89亿美元后，有望在纳斯达克上市首日大涨</title></head><body><p><span>8月5日</span><span> - </span>** 阿托维亚治疗公司（Attovia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>，股票代码： <span>ATTO.O</span>）在将美国首次公开募股（IPO）规模扩大至2.89亿美元后，其纳斯达克首日上市开盘价有望远高于发行价 </p><p>** 该股最新显示开盘价为每股24美元，而IPO发行价为17美元</p><p>** 总部位于加利福尼亚州圣卡洛斯的 ATTO（(<span>link</span>)）于周二晚间以每股17美元的价格售出1700万股 (link)，此次IPO规模已扩大 (<span>link</span>) </p><p>** ATTO公司致力于研发免疫介导性疾病的治疗方案，最初计划发行约1250万股，定价区间为每股15至17美元</p><p>** 其主要研发项目包括ATTO-1310，该药物正在开发用于治疗慢性瘙痒性疾病</p><p>** <a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>、Leerink Partners、<a href=\"https://laohu8.com/S/C\">花旗集团</a>和<a href=\"https://laohu8.com/S/RY\">加拿大皇家银行</a>资本市场担任此次发行的联合簿记管理人</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0882574139.USD","symbol_name":"富达环球消费行业基金A ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4T4421TN:1","article_id":"2657452303","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657452303","pubTimestamp":1785941615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Attovia Therapeutics 在IPO规模扩大至2.89亿美元后，有望在纳斯达克上市首日大涨8月5日-** 阿托维亚治疗公司（Attovia Therapeutics，股票代码：ATTO.O）在将美国首次公开募股（IPO）规模扩大至2.89亿美元后，其纳斯达克首日上市开盘价有望远高于发行价** 该股最新显示开盘价为每股24美元，而IPO发行价为17美元** 总部位于加利福尼亚","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0882574139.USD":"富达环球消费行业基金A ACC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","KBWB":"银行ETF-PowerShares","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4504":"桥水持仓","BK4207":"综合性银行","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","FTXO":"First Trust Nasdaq Bank ETF","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","BK4581":"高盛持仓","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","MNSH":"MNSN HLDGS INC.","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","IYF":"金融指数ETF-iShares Dow Jones","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2487616109.SGD":"JPM AMERICA EQUITY \"A\" (SGD) ACC","BK4566":"资本集团","TFNS":"T. Rowe Price Financials ETF","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","ATTO":"Attovia Therapeutics","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","BK4226":"数据处理及外包服务","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","IAI":"iShares Dow Jones U.S. Broker De","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC"},"translate_title":"Attovia Therapeutics is expected to surge on first day of Nasdaq listing after IPO expands to $289m","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TFNS":0.6,"IYF":0.6,"IAI":0.6,"FTXO":0.6,"KBWB":0.6,"MNSH":0.9,"ATTO":0.9},"content_text":"BUZZ-<a href=\"https://laohu8.com/S/ATTO\">Attovia Therapeutics</a> 在IPO规模扩大至2.89亿美元后，有望在纳斯达克上市首日大涨8月5日 - ** 阿托维亚治疗公司（Attovia Therapeutics，股票代码： ATTO.O）在将美国首次公开募股（IPO）规模扩大至2.89亿美元后，其纳斯达克首日上市开盘价有望远高于发行价 ** 该股最新显示开盘价为每股24美元，而IPO发行价为17美元** 总部位于加利福尼亚州圣卡洛斯的 ATTO（(link)）于周二晚间以每股17美元的价格售出1700万股 (link)，此次IPO规模已扩大 (link) ** ATTO公司致力于研发免疫介导性疾病的治疗方案，最初计划发行约1250万股，定价区间为每股15至17美元** 其主要研发项目包括ATTO-1310，该药物正在开发用于治疗慢性瘙痒性疾病** 摩根士丹利、Leerink Partners、花旗集团和加拿大皇家银行资本市场担任此次发行的联合簿记管理人","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding,corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}